Statin therapy in lupus-mediated atherogenesis: two birds with one stone?


The atherosclerotic process is accelerated in patients with systemic lupus erythematosus (SLE). In addition to a robust lipid-lowering effect, various immunomodulatory functions have been ascribed to statins. By virtue of the latter they may be able to reduce atherosclerotic vascular disease in SLE by inhibiting immune activation within the arterial wall and by attenuating lupus activity. The effects of statins on SLE as well as on lupus-mediated atherogenesis in vivo are discussed in this viewpoint.

DOI: 10.1136/ard.2010.133827
Citations per Year

560 Citations

Semantic Scholar estimates that this publication has 560 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Leuven2011StatinTI, title={Statin therapy in lupus-mediated atherogenesis: two birds with one stone?}, author={Sander I. van Leuven and Yanice V. Mendez-Fernandez and Erik S. G. Stroes and Paul Peter Tak and Amy S. Major}, journal={Annals of the rheumatic diseases}, year={2011}, volume={70 2}, pages={245-8} }